Olaparib: A Tale of Two Dosage Forms

Trevor N Christ
Additional contact information
Trevor N Christ: Department of Pharmacy, University of Chicago Medical Center, USA

Cancer Therapy & Oncology International Journal, 2018, vol. 9, issue 4, 99-101

Abstract: Olaparib is the first poly (ADP-ribose) polymerase (PARP) inhibitor approved by the FDA, with three approvals in two different cancer types. The original dosage form of olaparib was a 50 mg capsule, requiring 16 capsules per day for patients at full dose therapy which prompted development of a tablet dosage form with improved bioavailability. Herein, major trials for olaparib are reviewed and the two dosage forms are compared from a pharmacokinetic and clinical perspective.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555766.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555766.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:9:y:2018:i:4:p:99-101

DOI: 10.19080/CTOIJ.2018.09.555766

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().